Abstract | BACKGROUND: METHODS: RESULTS: Ten patients (31.3%, 95% Cl 15.2-47.4%) attained complete remission (CR) and seven had partial remission (PR). The overall response rate was 53.1% (95% Cl 35.8-70.4%). In eight of the 10 CR patients, the remission lasted for more than 8 months. The remaining two patients had CR of 5 and 6 months. The median duration of CR was 12.2 months (range 5-22 months). Myelosuppression with subsequent infections was the major toxicity. Severe leukopenia (WBC < 1000/microliter) lasted for an average of 12 days and thrombocytopenia (< 25,000/microliter) 18 days. One patient (3.1%) died of neutropenia-associated sepsis within 4 weeks after treatment. Non-myeloid toxicities included alopecia in 66% (28% grade 2, 22% grade 3), stomatitis in 72% (25% grade 2, 28% grade 3, 13% grade 4), hepatotoxicity in 9% (3% grade 2), renal toxicity in 13% (6% grade 2, 3% grade 3) and infection in 56% (18% grade 2, 25% grade 3, 13% grade 4). The majority of the responders relapsed within 2 years after ESHAP treatment. Median survival for all patients was 8.6 months. CONCLUSIONS: ESHAP is an active and tolerable regimen in Chinese patients with relapsed/refractory lymphoma, but the duration of remission is brief and without significant impact on survival.
|
Authors | W S Wang, T J Chiou, J H Liu, F S Fan, C C Yen, S L Tung, P M Chen |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 29
Issue 1
Pg. 33-7
(Jan 1999)
ISSN: 0368-2811 [Print] England |
PMID | 10073149
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cytarabine
- Etoposide
- Cisplatin
- Methylprednisolone
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cisplatin
(administration & dosage)
- Cytarabine
(administration & dosage)
- Drug Administration Schedule
- Etoposide
(administration & dosage)
- Female
- Humans
- Infusions, Intravenous
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Methylprednisolone
(administration & dosage)
- Middle Aged
- Recurrence
- Remission Induction
- Salvage Therapy
- Survival Analysis
|